Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT00413660

Public ClinicalTrials.gov record NCT00413660. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 5:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2B, Randomized, Double Blind, Placebo-Controlled, Multicenter Study To Compare 6 Dose Regimens Of CP-690,550 Vs. Placebo, Each Combined With Methotrexate, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate Alone

Study identification

NCT ID
NCT00413660
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
509 participants

Conditions and interventions

Interventions

  • CP-690,550 Drug
  • placebo Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2006
Primary completion
Jul 31, 2008
Completion
Jul 31, 2008
Last update posted
Jan 17, 2013

2007 – 2008

United States locations

U.S. sites
33
U.S. states
18
U.S. cities
29
Facility City State ZIP Site status
Pfizer Investigational Site Gilbert Arizona 85234
Pfizer Investigational Site Hot Springs Arkansas 71913
Pfizer Investigational Site Upland California 91786
Pfizer Investigational Site Denver Colorado 80204
Pfizer Investigational Site Newark Delaware 19713
Pfizer Investigational Site DeBary Florida 32713
Pfizer Investigational Site Lake Mary Florida 32746
Pfizer Investigational Site Ocala Florida 34474
Pfizer Investigational Site Orlando Florida 32804
Pfizer Investigational Site Tampa Florida 33614
Pfizer Investigational Site Zephyrhills Florida 33540
Pfizer Investigational Site Rockford Illinois 61103-3692
Pfizer Investigational Site Rockford Illinois 61107
Pfizer Investigational Site Dubuque Iowa 52002
Pfizer Investigational Site Frederick Maryland 21702
Pfizer Investigational Site Boston Massachusetts 02115
Pfizer Investigational Site Albany New York 12206-1043
Pfizer Investigational Site Binghamton New York 13905
Pfizer Investigational Site Charlotte North Carolina 28210
Pfizer Investigational Site Raleigh North Carolina 27609
Pfizer Investigational Site Dayton Ohio 45402
Pfizer Investigational Site Philladelphia Pennsylvania 19118
Pfizer Investigational Site West Reading Pennsylvania 19611-1124
Pfizer Investigational Site Greenville South Carolina 29601
Pfizer Investigational Site Austin Texas 78705
Pfizer Investigational Site Dallas Texas 75231
Pfizer Investigational Site Dallas Texas 75235
Pfizer Investigational Site Mesquite Texas 75150
Pfizer Investigational Site Seattle Washington 98104
Pfizer Investigational Site Seattle Washington 98122
Pfizer Investigational Site Tacoma Washington 98405-2308
Pfizer Investigational Site Tacoma Washington 98405
Pfizer Investigational Site Onalaska Wisconsin 54650

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00413660, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 17, 2013 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00413660 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →